Cancer immunotherapy gains acceptance; Alexza gets $15M loan; Bioengineering advances drug delivery;

> Mentor Capital has noted that with the featuring of Dendreon's Provenge prostate cancer vaccine on Fox News, cancer immunotherapy has come to a new point of popular acceptance. "One year ago only biotech investment reviews and medical journal reports followed pioneering cancer immunotherapy index member, Dendreon, as it climbed 1,000% in forty-five days." Mentor predicts other Dendreon-like companies in its "Cancer Immunotherapy Index (CII)" will also likely see a positive reaction. "Other CII companies are also pursuing treatments targeting cancer stem cells or brain, breast, melanoma and other cancer immunotherapies. Quite possibly, two or three markets of equal or greater size to Dendreon's will evolve, simply because there are two or three times the occurrence of cancer in the other cancer types that those companies are working on." Release

> Alexza Pharmaceuticals has executed a $15 million working capital loan agreement with Hercules Technology Growth Capital. Alexza's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. Alexza release

> In a keynote speech at the Association for Research in Vision and Ophthalmology meeting, Dr. Robert Langer said that advances in bioengineering will advance drug delivery and tissue regeneration. Report

> The past decade has seen a dramatic shift in terms of the types of approved injectable drugs, the diseases they target, and the devices used to deliver them, according to Greystone Associates. Report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.